Vantage Point: Finding a balance in pay for performace agreements

Share this article:

Pay for performance is not a new concept between health plan payers and providers, but very recently new risk/performance-based agreements between pharmas and payers have emerged. Different from traditional negotiated rebates and discounts to payers relative to preferred formulary status, these new agreements have provisions that mutually benefit the payers and manufacturers for keeping patients healthy.


In one agreement, Merck has negotiated with Cigna to provide their diabetes medication Januvia and Janumet on preferred formulary access (low patient copay), while Cigna provides compliance programs to improve patient adherence. Cigna in return would monitor their compliant patients on Januvia and their ability to control their diabetes. Merck will offer discounts to Cigna on those patients that are compliant and getting to goal, an incentive for Cigna.


Proctor & Gamble together with sanofi-aventis have negotiated an arrangement with a regional health plan in the midwest, Health Alliance, for the osteoporosis medication Actonel. Health Alliance will place Actonel on a preferred formulary position as compared to other osteoperosis meds, such as Boniva. Health Alliance will receive reimbursement for the cost of a fracture if the patient suffering it is compliant on Actonel. 


Although other countries over the past few years have negotiated performance-based arrangements for their healthcare systems, this is clearly a ground breaking phenomena here in the US. Given the natural contention between payers and manufacturers, it will be interesting to watch whether the current financial conditions driving these new agreements will persist.


Dea Belazi, PharmD, MPH is consulting practice leader, managed markets at Wolters Kluwer Health

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Vantage Point

Vantage Point: Payers—the "experts" in healthcare research

Vantage Point: Payers—the "experts" in healthcare research

Access to payers is about knowledge, about understanding what they do in their jobs

Vantage Point: Determining "fair market value"

Vantage Point: Determining "fair market value"

Should pharma formulate a super matrix to determine the FMV of research incentives?

Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials